MedPath

Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

Completed
Conditions
Pregnancy
Neonates
Interventions
First Posted Date
2008-07-30
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
2066
Registration Number
NCT00724789

A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)

Phase 4
Completed
Conditions
Contraception
Interventions
First Posted Date
2008-07-30
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
210
Registration Number
NCT00725413

Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)

Completed
Conditions
Rhinitis
Urticaria
Interventions
First Posted Date
2008-07-29
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
100
Registration Number
NCT00723736

Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

Completed
Conditions
Urticaria
Rhinitis
Interventions
First Posted Date
2008-07-29
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
3011
Registration Number
NCT00724698

Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

Completed
Conditions
Hypercholesterolemia
Hyperlipidemia
Coronary Heart Disease
Interventions
Drug: Statin
First Posted Date
2008-07-29
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
555
Registration Number
NCT00723723

Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)

Completed
Conditions
Primary Hypercholesterolemia
Interventions
Drug: INEGY
First Posted Date
2008-07-29
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
1663
Registration Number
NCT00724477

A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)

Completed
Conditions
Hypercholesterolemia
Familial Hypercholesterolemia
Homozygous Sitosterolemia
Interventions
First Posted Date
2008-06-25
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
1794
Registration Number
NCT00705211

Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)

Completed
Conditions
Hypercholesterolemia
Interventions
Drug: ezetimibe
Drug: statin
First Posted Date
2008-06-25
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
453
Registration Number
NCT00705081
© Copyright 2025. All Rights Reserved by MedPath